hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06271681, orgStudyIdInfo id: 2120135-1, briefTitle: Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: VA Sierra Nevada Health Care System, class: FED, collaborators name: Merck Sharp & Dohme LLC, descriptionModule briefSummary: The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster series of 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine 8 weeks later. Immune response will be assessed by opsonophagocytic assay reactivity and IgG Geometric mean concentration changes., conditionsModule conditions: Pneumococcal Vaccines, conditions: Immunosuppression, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: 15-valent pneumococcal conjugate vaccine, interventions name: 23-valent pneumococcal polysaccharide vaccine, outcomesModule primaryOutcomes measure: Change in opsonophagocytic assay (OPA) geometric mean titers (GMT), primaryOutcomes measure: Change in Immunoglobulin G (IgG) geometric mean concentrations (GMC), eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06271668, orgStudyIdInfo id: 23-2356, secondaryIdInfos id: R61DA057610, type: NIH, link: https://reporter.nih.gov/quickSearch/R61DA057610, briefTitle: Clinical Decision Support to Improve System Naloxone Co-prescribing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-09, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: University of Colorado, Denver, class: OTHER, collaborators name: National Institutes of Health (NIH), collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: The objective of this study is to evaluate the impact of a clinical decision support (CDS) alert to facilitate the co-prescribing of naloxone, an opioid overdose reversal agent, with high-risk opioid prescriptions. Prescribing naloxone with opioids is a best practice described in the 2022 US Center for Disease Control and Prevention (CDC) guidelines on opioid prescribing. The CDS can improve quality of care delivered by improving compliance with the guideline defined best practices. The project will compare CDS alert facilitated co-prescribing of naloxone with high-risk opioid prescriptions vs usual care to evaluate the effectiveness of the CDS alert for improving naloxone prescribing. The patients are not assigned to an intervention and will be receiving any changes in care as part of their routine medical care, rather than a specific intervention that is distinct from their usual medical care. The researchers hypothesize that the CDS alert will be acceptable to providers while increasing naloxone co-prescribing which will reduce the number of opioid overdoses in subsequent 6 months., conditionsModule conditions: Medication Abuse, conditions: Harm Reduction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200000, type: ESTIMATED, armsInterventionsModule interventions name: Naloxone Co-prescribing Clinical Decision Support (CDS), outcomesModule primaryOutcomes measure: Percentage of a high-risk opioid analgesic prescriptions receiving a co-prescription of naloxone, secondaryOutcomes measure: Clinical decision support (CDS) acceptance rate, secondaryOutcomes measure: Subsequent opioid overdose/poisonings rates, secondaryOutcomes measure: Naloxone dispensed rate, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 89 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Colorado Hospital, city: Aurora, state: Colorado, zip: 80045, country: United States, geoPoint lat: 39.72943, lon: -104.83192, hasResults: False
protocolSection identificationModule nctId: NCT06271642, orgStudyIdInfo id: 73822, briefTitle: Impact of Bluetooth Haptics Device Distraction on Mechanical Pain Thresholds Induced by PinPrick Stimulators, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: This is a prospective, crossover study of healthy participants evaluating the mechanical pain threshold for weighted pinprick stimuli., conditionsModule conditions: Pain, conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only, interventions name: Bluetooth Haptic Device (Control Frequency) + Needle Sham only, outcomesModule primaryOutcomes measure: Mechanical Pain Threshold, secondaryOutcomes measure: Mechanical pain sensitivity, secondaryOutcomes measure: Anxiety scores, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06271564, orgStudyIdInfo id: FDASU-Rec IM012415, briefTitle: Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-02-22, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: ZnO nanoparticles are now being widely researched for their anticancer properties. They show relatively high biocompatibility. They also show selective cytotoxicity against cancerous cells in in vitro condition compared with other nanoparticles. They can be further surface engineered to show increased selective cytotoxicity. The synthesis process of ZnO nanoparticles is relatively easy, with a wide variety of methods. Owing to these different methods of synthesis, their size and size distribution can be easily controlled. One of the novel methods of synthesis of ZnO is Magnetite ZnO-Fe3O4 Composite Nanoparticles.Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell., conditionsModule conditions: Oral Potentially Malignant Lesions, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Magnetite ZnO Composite Nanoparticles, interventions name: Topical Placebo Gel, outcomesModule primaryOutcomes measure: Change in the clinical size in Low to Moderate Dysplastic OPLs using Magnetite ZnO-Fe3O4 Composite NPs using standardized photographs of the oral marker lesion for each patient, secondaryOutcomes measure: Effect of Magnetite ZnO-Fe3O4 Composite NPs on the change of the degree of Dysplasia during histopathological examination using a biopsy, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry Ain shams University, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Nourhane Omara, Master's, role: CONTACT, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06271538, orgStudyIdInfo id: EP-USM-122023-001, briefTitle: Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2025-03-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: EP Plus Group Sdn Bhd, class: INDUSTRY, descriptionModule briefSummary: The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention., conditionsModule conditions: Irritable Bowel Syndrome, conditions: Gastrointestinal Diseases, conditions: Colonic Diseases, Functional, conditions: Intestinal Disease, conditions: Digestive System Disease, conditions: Pathologic Processes, conditions: Colonic Disease, conditions: Disease, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Skal Pro, interventions name: Placebo, outcomesModule primaryOutcomes measure: Improving the severity of symptoms in individuals with IBS, assessed by IBS Symptom Severity Scale (IBSSSS), secondaryOutcomes measure: Change in stool consistency (Bristol Stool Scale), assessed by daily stool diary, secondaryOutcomes measure: Change in stool frequency and satisfaction after passing stool, assessed by daily stool diary, secondaryOutcomes measure: Change in abdominal bloating, assessed by Bloating Severity Questionnaire (BSQ), secondaryOutcomes measure: Improvement in Quality of Life, assessed by EQ-5D-5L Questionnaire, secondaryOutcomes measure: Change in Visceral Sensitivity Index, secondaryOutcomes measure: Assessment of psychological dysfunction suing Catastrophizing Questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Universiti Sains Malaysia, city: Kubang Kerian, state: Kelantan, zip: 16150, country: Malaysia, contacts name: Yeong Yeh Lee, MD, PhD, role: CONTACT, phone: +6097676846, phoneExt: 6845, email: yylee@usm.my, contacts name: Yeong Yeh Lee, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Thai Hau Koo, MD, role: SUB_INVESTIGATOR, geoPoint lat: 6.09123, lon: 102.27938, hasResults: False
protocolSection identificationModule nctId: NCT06271525, orgStudyIdInfo id: P.T.REC/012/002532, briefTitle: Effect of Cupping Therapy on Nitric Oxide Level in Patients With Cervical Spondylosis, acronym: CT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2024-05-20, completionDateStruct date: 2024-05-20, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Shady Abdelsattar Refaat, class: OTHER, descriptionModule briefSummary: this study will be conducted to investigate the effect of cupping therapy on the nitric oxide level in patients with cervical spondylosis, conditionsModule conditions: Cervical Spondylosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: cupping therapy, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: cupping therapy, outcomesModule primaryOutcomes measure: the nitric oxide level, secondaryOutcomes measure: cervical range of motion, secondaryOutcomes measure: pain intensity, eligibilityModule sex: ALL, minimumAge: 24 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06271512, orgStudyIdInfo id: REG-501, briefTitle: A Study of Participants With β-Thalassemia Treated With Betibeglogene Autotemcel, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-23, primaryCompletionDateStruct date: 2043-12, completionDateStruct date: 2043-12, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: bluebird bio, class: INDUSTRY, collaborators name: Center for International Blood and Marrow Transplant Research, descriptionModule briefSummary: The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel., conditionsModule conditions: Beta-Thalassemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: No Intervention, outcomesModule primaryOutcomes measure: Number of Participants who Experience Each Individual Adverse Events of Interest (AEIs), secondaryOutcomes measure: Number of Participants with Serious Adverse Events (SAEs), secondaryOutcomes measure: Number of Participants with beti-cel related AEs, secondaryOutcomes measure: Event-Free Survival, secondaryOutcomes measure: Percentage of Participants Achieving Transfusion Independence, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UCSF Benioff Children's Hospitals, status: RECRUITING, city: Oakland, state: California, zip: 94609, country: United States, geoPoint lat: 37.80437, lon: -122.2708, hasResults: False
protocolSection identificationModule nctId: NCT06271499, orgStudyIdInfo id: AnkaraU-Smart-cannulation, briefTitle: The Effect of Using Smart Glasses Integrated Ultrasonography on Radial Artery Catheterization, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-08-01, primaryCompletionDateStruct date: 2022-12-28, completionDateStruct date: 2023-02-14, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Ankara University, class: OTHER, collaborators name: Ayşegül Güven, collaborators name: Bengi Safak, collaborators name: Ahmet Onat Bermede, descriptionModule briefSummary: The use of Ultrasonography (USG) in arterial catheterization, in which the comfort of the practitioner and hand-eye coordination become very important, is frequently needed by anesthesiologists in their daily practice. The aim of this study is to evaluate the success rate and anesthesiologist's satisfaction between two practitioners with different levels of experience in radial artery catheterization with smart glasses USG., conditionsModule conditions: Catheterization, conditions: Cannulation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ACTUAL, armsInterventionsModule interventions name: Radial artery catheterization with USG, interventions name: Radial artery catheterization with smart glasses integrated UGG, outcomesModule primaryOutcomes measure: The success rate, primaryOutcomes measure: The anesthesiologist's satisfaction, secondaryOutcomes measure: The cannulation time, secondaryOutcomes measure: Complications, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara University Medical Faculty, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06271486, orgStudyIdInfo id: RC. 40.5.2023, briefTitle: Pregabalin in Treatment of Postdural Puncture Headache, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-08-15, completionDateStruct date: 2024-08-15, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Al-Azhar University, class: OTHER, collaborators name: Benha University, descriptionModule briefSummary: Lumbar puncture (LP), often known as a "spinal tap," is a standard medical technique pioneered in the late 1900s by Heinrich Quincke. It involves the retrieval and analysis of cerebrospinal fluid (CSF) from the spinal cord, serving as the benchmark for diagnosing conditions like subarachnoid hemorrhage, meningitis, and specific neurological conditions. Pregabalin, an anticonvulsant medicine that blocks calcium entry, is used to treat a variety of diseases. It has been used to relieve pain in a variety of patient groups, including those with chronic pain, epilepsy, and anxiety disorders, conditionsModule conditions: Postdural Puncture Headache, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Pregabalin 75mg, interventions name: An epidural blood patch (EBP), interventions name: conservative treatment., outcomesModule primaryOutcomes measure: the incidence of complete relief, secondaryOutcomes measure: The intensity of the headache, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Neveen Kohaf, status: RECRUITING, city: Tanta, zip: 11865, country: Egypt, contacts name: Neveen Kohaf, role: CONTACT, phone: +201060383012, email: nevenabdo@azhar.edu.eg, contacts name: Nahed F. Abo-Elmatey, M.D, role: PRINCIPAL_INVESTIGATOR, contacts name: Hany Bauiomy, M.D, role: PRINCIPAL_INVESTIGATOR, contacts name: Ahmed M. Abosakaya, M.D, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06271473, orgStudyIdInfo id: AinShamsU3, briefTitle: Effect of PPV+ILM Peeling +/- Subretinal Injection of Ringer Lactate in Management of Nontractional Refractory DME, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-30, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of combined pars plana vitrectomy and planned foveal detachment through subretinal injection of ringer's solution in patients with non-tractional refractory diabetic macular edema., conditionsModule conditions: Efficacy, conditions: Safety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 20 eyes of 20 patients will be divided randomly into 2 groups:* Group (A): 10 eyes subjecting to vitrectomy + ILM peeling only* Group (B): 10 eyes subjecting to vitrectomy + ILM peeling + planned foveal detachment via subretinal injection of ringer's solution., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution., outcomesModule primaryOutcomes measure: change in CMT by OCT at final visit, secondaryOutcomes measure: change in BCVA at final visit, otherOutcomes measure: any surgical complication or recurrence of DME, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ain Shams university, status: ACTIVE_NOT_RECRUITING, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, locations facility: Ain Shams university, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Azza MA Said, MD, role: CONTACT, phone: +201006228992, email: dr_azza_22@hotmail.com, contacts name: David G Samuel, Msc, role: CONTACT, phone: +201064442469, email: david.samuel.ophth@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06271460, orgStudyIdInfo id: 2023-21-728, briefTitle: Disability in Patients With Non-specific Chronic Low Back Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Acibadem University, class: OTHER, descriptionModule briefSummary: To investigate the reliability and sensitivity of the Turkish versions of the Roland-Morris Disability Questionnaire, The Quebec Back Pain Disability Scale, and the Oswestry Disability Index in patients with chronic non-specific low back pain and to increase confidence in their use in clinical practice and research by determining the most appropriate minimal clinically significant difference values for this patient population., conditionsModule conditions: Chronic Nonspecific Low Back Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Traditional physiotherapy, outcomesModule primaryOutcomes measure: Visual Analog Scale, primaryOutcomes measure: The Roland-Morris Disability Questionnaire, primaryOutcomes measure: The Quebec Back Pain Disability Scale, primaryOutcomes measure: The Oswestry Disability Index, primaryOutcomes measure: The Perceived Global Impact, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Acıbadem Health Group, status: RECRUITING, city: Istanbul, state: None Selected, zip: 34752, country: Turkey, contacts name: Elif E Safran, asst. prof., role: CONTACT, phone: 500 4047, phoneExt: 216, email: elif.bayraktar@acibadem.edu.tr, contacts name: Irmak Çavuşoğlu, asst. prof., role: CONTACT, phone: 500 4184, phoneExt: 216, email: irmak.cavusoglu@acibadem.edu.tr, contacts name: Elif E Safran, asst. prof., role: PRINCIPAL_INVESTIGATOR, contacts name: Irmak Çavuşoğlu, asst. prof., role: PRINCIPAL_INVESTIGATOR, contacts name: Nuray Alaca, assoc. prof., role: SUB_INVESTIGATOR, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False